Skip to main content

Table 1 Baseline clinical and hemodynamic data (n = 54)

From: Quality of life as a prognostic marker in pulmonary arterial hypertension

Age (years)

44 ± 12

Sex (f/m)

45/9

Etiology n (%)

 

Idiopathic

37 (68)

Associated to

 

Schistosomiasis

7 (13)

CTD

8 (15)

CHD

2 (4)

NYHA functional class n (%)

 

II

14 (26)

III

28 (52)

IV

12 (22)

6MWT (m)

418 ± 121

mPAP (mmHg)

64 ± 17

PAOP (mmHg)

10 ± 2

Cardiac output (L/min)

4 ± 1

PVR (WU)

15 ± 8

Therapy n (%)

 

ERA

46 (85)

PDE-5 inhibitors

8 (15)

  1. CTD Connective tissue disease, CHD Congenital heart disease, NYHA New York Heart Association, 6MWT Length in non-encouraged six-minute-walk test, RAP Right Atrial Pressure, mPAP Mean Pulmonary Artery Pressure, PAOP Pulmonary Artery Occlusion Pressure, PVR Pulmonary Vascular Resistance, ERA Endothelin Receptor Antagonists, PDE-5 Phosphodiesterase-5 inhibitor.
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us